2015-08-03T13:32:30-05:00 2014-12-31 954303700 JOHN S BALISY & COMPANY 23792 ROCKFIELD BLVD STE 140 LAKE FOREST CA 92630 990 2014-01-01 200299958 CURE DUCHENNE CURE 9498722552 1400 QUAIL STREET NO 110 NEWPORT BEACH CA 92660 DEBRA MILLER PRESIDENT 9498722552 2015-07-23 JOHN S BALISY COMPANY P01385861 9495407519 2014 2016-02-25 16:41:14Z DEBRA MILLER 1400 QUAIL STREET STE 110 NEWPORT BEACH CA 92660 4957483 0 X WWW.CUREDUCHENNE.ORG X 2003 CA COORDINATING AND FUNDING RESEARCH NECESSARY TO FIND A CURE FOR DUCHENNE MUSCULAR DYSTROPHY. ALSO, IMPROVING THE CARE AND HEALTH OF DUCHENNE MUSCULAR DISTROPHY PATIENTS. 11 11 6 0 0 0 1457692 1320395 0 0 41362 2534631 376249 197771 1875303 4052797 467653 164994 0 0 689723 675017 0 0 223039 799037 706800 1956413 1546811 -81110 2505986 2700223 7112452 46422 69394 2653801 7043058 X CURE DUCHENNE IS A NOT-FOR-PROFIT ORGANIZATION DEDICATED TO COORDINATING AND FUNDING RESEARCH NECESSARY TO FIND A CURE FOR DUCHENNE MUSCULAR DYSTROPHY, INCREASING PUBLIC AWARENESS FOR DUCHENNE MUSCULAR DYSTROPHY, AND IMPROVING THE CARE AND HEALTH DUCHENNE MUSCULAR DYSTROPHY PATIENTS. 0 0 1188023 164994 CURE DUCHENNE WAS ORGANIZED IN 2003 WITH A MISSION TO FUND RESEARCH NECESSARY TO FIND A CURE FOR DUCHENNE MUSCULAR DYSTROPHY, AND IMPROVING THE CARE AND HEALTH OF DUCHENNE MUSCULAR DYSTROPHY PATIENTS. 1188023 1 1 0 0 0 0 0 0 0 0 1 1 0 0 1 0 1 0 0 0 0 1 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 54 0 1 6 0 0 0 0 0 0 0 0 0 X 11 11 1 0 0 0 0 0 0 1 1 0 0 0 1 1 1 1 1 1 1 0 CA X DEBRA MILLER 9497214063 1400 QUAIL STREET STE 110 NEWPORT BEACH CA 92660 PAUL MILLER SECRETARY 10.00 X X 0 0 0 DEBRA MILLER PRESIDENT 40.00 X X 180000 0 0 JEFFREY GOFFMAN DIRECTOR 1.00 X 0 0 0 RON PHILIP DIRECTOR 1.00 X 0 0 0 TOM SCRANTON DIRECTOR 1.00 X 0 0 0 KEVIN DORSEY DIRECTOR 1.00 X 0 0 0 RYAN WILLIAMS DIRECTOR 1.00 X 0 0 0 EVONNE SEPSIS DIRECTOR 1.00 X 0 0 0 ELAINE WU DIRECTOR 1.00 X 0 0 0 TJ FARNSWORTH DIRECTOR 1.00 X 0 0 0 GEORGE BLANK DIRECTOR 1.00 X 0 0 0 KAREN E HARLEY VICE-PRESIDENT 40.00 X 120000 0 0 MICHAEL G KELLY CHIEF SCIENTIFIC OFFICER 40.00 X 168384 0 0 ANDREW HOYER SENIOR DIRECTOR OF DEVELOPMENT 40.00 X 111000 0 0 579384 0 0 4 0 1 0 ANONYMOUS 9140 IRVINE CENTER DRIVE IRVINE CA 92618 FUNDRAISING 146823 1 1316427 3968 3968 1320395 22594 22594 2941345 429308 2512037 2512037 2512037 673149 1316427 475378 197771 197771 4052797 22594 0 2709808 162494 162494 2500 2500 579384 534384 45000 52195 22916 29279 43438 20167 3851 19420 57761 50804 4885 2072 33535 33535 2424 2324 100 11717 7417 4096 204 31682 18270 5556 7856 45395 22203 10958 12234 102758 80528 193 22037 462 462 59761 44874 840 14047 OUTSIDE CONTRACT SERVIC 302912 234151 30988 37773 BANK & CREDIT CARD CHAR 16909 602 2392 13915 PRINTING & REPRODUCTION 13620 1728 3936 7956 POSTAGE & DELIVERY EXPE 9432 94 1912 7426 18432 5483 9129 3820 1546811 1188023 135749 223039 205083 238548 290943 1991777 626568 649130 17063 16372 1078 691 1574388 4230218 131 56 2032 2032 2700223 7112452 46422 69394 46422 69394 X 2653801 7043058 2653801 7043058 2700223 7112452 2505986 1883271 0 X 0 0 0 X 1258555 1271672 2386942 2346536 1993544 9257249 1258555 1271672 2386942 2346536 1993544 9257249 9257249 34789 34789 38984 41362 22594 172518 9429767 0.98170 0.98160 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 17063 16372 691 691 INVESTMENT IN PROSENSA HOLDINGS, N.V. (SEE FOOTNOTE 1) 3022163 F INVESTMENTS HELD 1208055 F 4230218 CREDIT CARD PAYABLE 13442 ACCRUED EXPENSES 55952 69394 5936067 1883270 1883270 4052797 0 4052797 1546811 0 1546811 0 1546811 0 0 0 0 0 0 0 0 0 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 2500 0 0 0 0 0 0 X 0 ANONYMOUS 9140 IRVINE CENTER DRIVE IRVINE CA 92618 GOLF TOURNAMENT/ANNUAL GALAS 0 1079446 146823 1079446 1079446 146823 1079446 CA GETZLAF GOLF TOURNAMENT 301544 50000 251544 154161 FUNDRAISER-NEWPORT BEACH GALA 362799 118250 244549 105758 13 1325233 1148177 177056 215459 1989576 1316427 673149 475378 475378 197771 SCHEDULE G, PART I, LINE 2B, COLUMN (V) DURING 2014, THE ORGANIZATION PAID THE FUNDRAISER $146,823. THESE PAYMENTS REPRESENT SERVICES RENDERED DURING THE FUNDRAISING EVENTS, INCLUDING ORGANIZING AND COORDINATING THE FUNCTIONS. 0 NATIONWIDE CHILDREN'S HOSPITAL 700 CHILDRENS DRIVE COLUMBUS OH 43205 311036372 134300 EDUCATION / OUTREACH / RESEARCH CHILDREN'S RESEARCH INSTITUTE 111 MICHIGAN AVE NW WASHINGTON DC 20010 521654453 8700 EDUCATION / OUTREACH / RESEARCH EFFICACY OF DUCHENNE TRIALS CO SUSAN WARD 5B LANCASTER STREET CAMBRIDGE MA 02140 12500 EDUCATION / OUTREACH / RESEARCH OTHER MISCELLANEOUS GRANTS 1400 QUAIL STREET NEWPORT BEACH CA 92660 6994 EDUCATION / OUTREACH / RESEARCH X 0 0 0 0 0 0 0 0 0 DEBRA MILLER PRESIDENT 120000 0 60000 0 0 0 0 0 0 0 180000 0 0 0 KAREN E HARLEY VICE-PRESIDENT 120000 0 0 0 0 0 0 0 0 0 120000 0 0 0 MICHAEL G KELLY CHIEF SCIENTIFIC OFFICER 168384 0 0 0 0 0 0 0 0 0 168384 0 0 0 ANDREW HOYER SENIOR DIRECTOR OF DEVELOPMENT 111000 0 0 0 0 0 0 0 0 0 111000 0 0 0 FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES CURE DUCHENNE MADE TWO SEPARATE INVESTMENTS IN PROSENSA HOLDINGS, N.V., A PRIVATELY HELD COMPANY LOCATED IN THE NETHERLANDS. IN NOVEMBER 2004, CURE DUCHENNE INVESTED $336,250. IN DECEMBER 2006, A PORTION OF A NON-INTEREST BEARING LOAN IN THE AMOUNT OF $485,425 WAS CONVERTED TO EQUITY COMMON SHARES. SEE BALANCE SHEET AND FOOTNOTE NO. 1. THE FUNDS CONTRIBUTED BY CURE DUCHENNE ARE RESTRICTED FOR RESEARCH TO FINDING A CURE FOR DUCHENNE MUSCULAR DYSTROPHY. THE ORGANIZATION MONITORS PROSENSA'S RESEARCH ACTIVITIES TO ENSURE PROPER UTILIZATION OF THE CONTRIBUTED FUNDS. THE EQUITY INTEREST MAY PROVIDE THE ORGANIZATION WITH ADDTIONAL CAPITAL IN THE FUTURE TO FUND OTHER RESEARCH PROJECTS FOR DUCHENNE MUSCULAR DYSTROPHY. IN 2013, PROSENA HOLDING, N.V. BECAME A PUBLICILY TRADED COMPANY LISTED ON THE NASDAQ. AS SUCH, THE VALUE REFLECTED ON THE BALANCE SHEET AT DECEMBER 31, 2013 IS CARRIED AT MARKET VALUE. DURING 2014, PROSENA HOLDINGS, N.V. WAS PURCHASED BY BIOMARIN PHARMACUETICALS, INC. BIOMARIN HAS DECIDED TO DE-LIST PROSENA HOLDING, N.V. FROM THE NASDAQ AND WILL BE PURCHASING BACK ALL OF PROSENA HOLDING, N.V'S OUTSTANDING STOCK. THE VALUE REFLECTED ON THE BALANCE SHEET AT DECEMBER 31, 2014 IS CARRIED AT COST OF $17.75 PER SHARE, WHICH IS THE AGREED UPON PRICE BETWEEN BIOMARIN PHARMACEUTICAL AND PROSENA HOLDING, N.V. FOR PROSENA'S OUTSTANDING STOCK. FORM 990, PART VI, SECTION A, LINE 2 DEBRA AND PAUL MILLER HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11 FORM 990 WILL BE AVAILABLE TO THE BOARD TO REVIEW PRIOR TO FILING AT THE REGULARLY SCHEDULE BOARD MEETINGS. HOWEVER, A LIMITED NUMBER OF BOARD MEMBERS WILL REVIEW THE ENTIRE FORM 990 PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD OF DIRECTORS ARE REQUIRED TO REVIEW AND SIGN THE CONFLICT OF INTEREST POLICY AT LEAST ANNUALLY. THE BOARD MEMBER MUST INFORM THE REST OF THE BOARD IF A CONFLICT ARISES OR IF IT EXISTS. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF TOP MANAGEMENT AND OFFICERS OF THE ORGANIZATION ARE REVIEWED BY INDEPENDENT LEGAL COUNSEL AND SUBMITTED TO THE BOARD MEMBERS FOR APPROVAL. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANZIATION'S AUDITED FINANCIAL STATEMENTS AND FORM 990 ARE AVAILABLE TO THE PUBLIC UPON REQUEST. FOOTNOTE NO. 1 IN RE: INVESTMENT IN PROSENA HOLDINGS, N.V. THE ORGANIZATION MADE TWO SEPARATE INVESTMENTS IN PROSENSA HOLDINGS, N.V., A PRIVATELY HELD COMPANY LOCATED IN THE NETHERLANDS. IN NOVEMBER 2004, CURE DUCHENNE INVESTED $336,250. IN DECEMBER 2006, A PORTION OF A NON-INTEREST BEARING LOAN IN THE AMOUNT OF $485,425 WAS CONVERTED TO EQUITY COMMON SHARES. THESE CONTRIBUTED FUNDS ARE RESTRICTED FOR USE IN RESEARCH DIRECTLY RELATED TO FINDING A CURE FOR DUCHENNE MUSCULAR DYSTROPHY. CURE DUCHENNE'S BOARD MONITORS PROSENSA'S RESEARCH ACTIVITIES AND AUTHORIZES RELEASE OF ADDITIONAL FUNDS TO PROSENSA FOR FURTHER RESEARCH AS OBJECTIVES ARE MET BY PROSENSA. CURE DUCHENNE RECEIVED A EQUITY INTEREST IN PROSENSA FOR THE CONTRIBUTIONS. THE EQUITY INTEREST ENABLES CURE DUCHENNE TO MONITOR PROSENSA'S RESEARCH EFFORTS TO FINDING A CURE FOR DUCHENNE MUSCULAR DYSTROPHY. ADDITIONALLY, THE EQUITY INTEREST IN PROSENSA MAY PROVIDE CURE DUCHENNE WITH ADDITIONAL CAPITAL IN THE FUTURE TO FUND OTHER RESEARCH PROJECTS FOR DUCHENNE MUSCULAR DYSTROPHY. IN 2013, PROSENA HOLDING, N.V. BECAME A PUBLICILY TRADED COMPANY LISTED ON THE NASDAQ. AS SUCH, THE VALUE REFLECTED ON THE BALANCE SHEET AT DECEMBER 31, 2013 IS CARRIED AT MARKET VALUE. DURING 2014, PROSENA HOLDINGS, N.V. WAS PURCHASED BY BIOMARIN PHARMACUETICALS, INC. BIOMARIN HAS DECIDED TO DE-LIST PROSENA HOLDING, N.V. FROM THE NASDAQ AND WILL BE PURCHASING BACK ALL OF PROSENA HOLDING, N.V'S OUTSTANDING STOCK. THE VALUE REFLECTED ON THE BALANCE SHEET AT DECEMBER 31, 2014 IS CARRIED AT COST OF $17.75 PER SHARE, WHICH IS THE AGREED UPON PRICE BETWEEN BIOMARIN PHARMACEUTICAL AND PROSENA HOLDING, N.V. FOR PROSENA HOLDING'S OUTSTANDING STOCK.